NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

BeOne Medicines AG (ONC) Stock Analysis

BeOne Medicines AG (ONC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ONC

$358.26

−$4.42 (−1.22%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ONC with… →

ONC Key Statistics

As of Sep 4, 2026
Trading
Open
$359.71
Previous Close
$362.68
Day's Range
357.58–362.67
52-Week Range
253.95–385.22
Volume
202.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.52
Valuation
Market Cap
$40.53B
P/E Ratio
64.09
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
34.84
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.77
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.61
EPS (ttm)Profit attributable to each share over the last twelve months.
5.59
Financials (FY)
Revenue (FY)
$5.34B+40.23%
Net Income (FY)
$286.93M
Profit marginThe share of revenue left as profit after all costs and taxes.
10.70%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
104.27M
1-Year Return
+12.40%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
363.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ONC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+17.92%
2025+64.48%
2024+2.41%
2023−18.00%
2022−18.82%
2021+4.85%
2020+55.88%
2019+18.18%
2018+43.53%
2017+221.87%
2016 (partial year)+14.39%

As of September 4, 2026.

ONC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.34B$286.93M5.4%
2024$3.81B−$644.79M−16.9%
2023$2.46B−$881.71M−35.9%
2022$1.42B−$2.00B−141.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.34B$4.67B$447.14M$286.93M5.4%
2024$3.81B$3.22B−$568.20M−$644.79M−16.9%
2023$2.46B$2.08B−$1.21B−$881.71M−35.9%
2022$1.42B$1.13B−$1.79B−$2.00B−141.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ONC Valuation vs Biotechnology Median

Median of 656 stocks
MetricONCBiotechnology medianvs median
P/E64.0912.575.1x the median
P/S ratio6.6115.2657% below
Profit margin10.70%0.00%10.7 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BeOne Medicines AG (ONC) is capitalised at $40.53B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12,000.

ONC last closed at $358.26 on September 4, 2026. That is −$4.42 (−1.22%) against the previous close. Over the past 52 weeks the price has ranged from $253.95 to $385.22. The latest close sits 41.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.34B. Against the prior fiscal year total of $3.81B, that is a change of +40.23%. Net income for the same year was $286.93M. Profit margin runs at 10.7%. That is 10.7 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 5.59.

Across the 4 fiscal years on file, revenue moves from $1.42B in 2022 to $5.34B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

ONC trades at a trailing price-to-earnings ratio of 64.09. That is 5.1 times the Biotechnology median of 12.57. On forward earnings the ratio is 34.84. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.77. Measured against sales, the shares trade at 6.61 times revenue. On price-to-sales that is 56.68% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +12.40%. Measured over 10 years, that is +28.37% a year compounded. Beta against the wider market is reported at 0.52. Annualized volatility over the trailing 10 years is 55.54%.

Growth & Income

No dividend is on file for ONC.

The strongest complete calendar year on file is 2017 at +221.87%; the weakest is 2022 at −18.82%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the price is +17.92% year to date.

Peer Comparison

BeOne Medicines AG (ONC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BeOne Medicines AG ONC $40.53B 64.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. BeOne Medicines AG trades at a P/E of 64.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 RPRX

Royalty Pharma plc

$36.96B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Visit website →